Date: 2011-04-27
Type of information: R&D agreement
Compound: Sprint™
Company: Beactica (Sweden) Janssen Research & Development - J&J (Belgium-USA)
Therapeutic area: undisclosed
Type agreement: R&D
collaboration
services
Action mechanism: Sprint™ is a SPR (surface plasmon resonance)-based small molecule drug discovery platform.
Disease: undisclosed
Details: Beactica, a Swedish fragment-based drug discovery company, has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint™, to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
